Core Insights - PAVmed Inc. completed a private placement equity financing for its subsidiary Veris Health, raising $2.5 million at a pre-money valuation of approximately $35 million [1][2][3] Group 1: Financing Details - Veris Health sold shares at $1.40 per share, with proceeds aimed at advancing its implantable physiological monitor through FDA clearance expected in 2026 [2][3] - The financing follows a previous $2.4 million round completed earlier in the year, indicating ongoing investor interest and confidence in Veris Health's potential [1][2] Group 2: Product and Technology - Veris Health focuses on personalized cancer care through remote patient monitoring using implantable biologic sensors and connected external devices [2][4] - The Veris Cancer Care Platform integrates remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration to enhance patient care [4][5] Group 3: Strategic Importance - The financing is seen as a significant milestone for both PAVmed and Veris, providing necessary capital to fund the development and commercialization of the implantable physiological monitor [3][4] - The monitor is expected to serve as a key differentiator in the market, enhancing personalized care in conjunction with the Veris Cancer Care Platform [3][5]

Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery networkNEW YORK, June 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, int ...

Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – JamesNEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic ...

Core Points - Lucid Diagnostics Inc. will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the close of U.S. equity markets on June 27, 2025, as part of the 2025 annual reconstitution [1][2] - This inclusion is expected to enhance Lucid's visibility and access to a broader range of institutional investors, reflecting the company's progress in enhancing shareholder value over the past year [2] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [4] - The company's EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device are the first and only commercially available tools aimed at preventing cancer through early detection of esophageal precancer in at-risk patients [4] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes, indicating the significance of these indices for institutional investors and investment managers [2]

Lucid Diagnostics (LUCD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Company Participants Matt Riley - Director of Investor RelationsLishan Aklog - Chairman & CEODennis McGrath - CFO Conference Call Participants Mark Massaro - MD & Senior Equity Research AnalystKyle Mikson - Managing Director & Senior Research AnalystMike Matson - Senior Equity Research AnalystJeremy Pearlman - Equity AnalystRoss Osborn - Director, Lead Research Analyst - MedTech and DiagnosticsEdward Woo - Director of Research & Senior ...

Lucid Diagnostics (LUCD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the Lucid Diagnostics First Quarter twenty twenty five Business Update Conference Call. Please note this event is being recorded. I would now like to turn the conference call over to Mr. Matt Reilly, Lucid Diagnostics Senior Director of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Good morning, everyone. Thank you for participating in today's business update call. Joining me to ...

Core Viewpoint - Lucid Diagnostics Inc. has secured capital to extend its operational runway significantly, positioning the company to capitalize on upcoming reimbursement milestones and accelerate commercialization efforts for its EsoGuard product [4][6]. Business Highlights - The company is expanding cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage [4]. - A partnership with a major health system has been established to launch a comprehensive EsoGuard esophageal precancer testing program, enhancing access for at-risk patients [6]. - The company has launched the "Embrace the Future" campaign to promote its EsoCheck® Cell Collection Device, which features innovative technology compared to traditional methods [6]. - A National Cancer Institute-sponsored study has shown that EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, potentially increasing market opportunity by up to 70% [6]. Financial Results - For the three months ended March 31, 2025, Lucid processed 3,034 EsoGuard tests and recognized $0.8 million in revenue from EsoGuard [6]. - The company reported operating expenses of approximately $13.3 million, including $1.0 million in stock-based compensation, leading to a GAAP net loss of approximately $36.0 million or $(0.52) per share [6][9]. - The non-GAAP adjusted loss for the same period was approximately $11.2 million or $(0.16) per share [7][11]. - As of March 31, 2025, Lucid had cash and cash equivalents of $25.2 million, an increase from $22.4 million as of December 31, 2024, and completed a public offering for net proceeds of $16.1 million [10].

Conference Call and Webcast at 8:30 AM Eastern TimeNEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a busine ...

Conference Call and Webcast at 8:30 AM Eastern TimeNEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, inclu ...

Lucid Diagnostics (LUCD) Q4 2024 Earnings Call March 24, 2025 08:30 AM ET Company Participants Matt Riley - Director of Investor RelationsLishan Aklog - Chairman & CEODennis McGrath - CFOAnthony Vendetti - Executive Managing Director Conference Call Participants Kyle Mikson - Managing Director & Senior Research AnalystMark Massaro - Managing Director - Senior Equity Research AnalystMike Matson - Senior Equity Research AnalystEdward Woo - Director of Research & Senior Analyst Operator Good morning and welcom ...